Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David MacManus

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Journal of Neurology, Neurosurgery, and Psychiatry|December 18, 2024
Optical coherence tomography in secondary progressive multiple sclerosis: cross-sectional and longitudinal exploratory analysis from the MS-SMART randomised controlled trialFloriana De Angelis, James R Cameron, Arman Eshaghi, et al.
Lancet (London, England)|March 25, 2014
Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trialJeremy Chataway, Nadine Schuerer, Ali Alsanousi, et al.
Annals of Clinical and Translational Neurology|September 18, 2022
Remyelination varies between and within lesions in multiple sclerosis following bexaroteneJ William L Brown, Ferran Prados, Daniel R Altmann, et al.
Journal of Magnetic Resonance Imaging : JMRI|October 3, 2023
Longitudinal Metabolite Changes in Progressive Multiple Sclerosis: A Study of 3 Potential Neuroprotective TreatmentsNevin A John, Bhavana S Solanky, Floriana De Angelis, et al.
European Journal of Neurology|June 15, 2023
Cardiovascular risk factors in secondary progressive multiple sclerosis: A cross-sectional analysis from the MS-STAT2 randomized controlled trialThomas Williams, Nevin John, Alberto Calvi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 9, 2021
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension studyHans-Peter Hartung, Tobias Derfuss, Bruce Ac Cree, et al.
Neuroimage. Reports|September 27, 2024
Investigating the relationship between thalamic iron concentration and disease severity in secondary progressive multiple sclerosis using quantitative susceptibility mapping: Cross-sectional analysis from the MS-STAT2 randomised controlled trialThomas Williams, Nevin John, Alberto Calvi, et al.
BMJ Open|September 1, 2018
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosisPeter Connick, Floriana De Angelis, Richard A Parker, et al.
The Lancet. Neurology|January 26, 2020
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trialJeremy Chataway, Floriana De Angelis, Peter Connick, et al.
Brain : a Journal of Neurology|December 12, 2023
Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndromeHelmut Butzkueven, Anne-Louise Ponsonby, Mark S Stein, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Journal of Neurology, Neurosurgery, and Psychiatry|December 18, 2024
Optical coherence tomography in secondary progressive multiple sclerosis: cross-sectional and longitudinal exploratory analysis from the MS-SMART randomised controlled trialFloriana De Angelis, James R Cameron, Arman Eshaghi, et al.
Lancet (London, England)|March 25, 2014
Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trialJeremy Chataway, Nadine Schuerer, Ali Alsanousi, et al.
Annals of Clinical and Translational Neurology|September 18, 2022
Remyelination varies between and within lesions in multiple sclerosis following bexaroteneJ William L Brown, Ferran Prados, Daniel R Altmann, et al.
Journal of Magnetic Resonance Imaging : JMRI|October 3, 2023
Longitudinal Metabolite Changes in Progressive Multiple Sclerosis: A Study of 3 Potential Neuroprotective TreatmentsNevin A John, Bhavana S Solanky, Floriana De Angelis, et al.
European Journal of Neurology|June 15, 2023
Cardiovascular risk factors in secondary progressive multiple sclerosis: A cross-sectional analysis from the MS-STAT2 randomized controlled trialThomas Williams, Nevin John, Alberto Calvi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 9, 2021
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension studyHans-Peter Hartung, Tobias Derfuss, Bruce Ac Cree, et al.
Neuroimage. Reports|September 27, 2024
Investigating the relationship between thalamic iron concentration and disease severity in secondary progressive multiple sclerosis using quantitative susceptibility mapping: Cross-sectional analysis from the MS-STAT2 randomised controlled trialThomas Williams, Nevin John, Alberto Calvi, et al.
BMJ Open|September 1, 2018
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosisPeter Connick, Floriana De Angelis, Richard A Parker, et al.
The Lancet. Neurology|January 26, 2020
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trialJeremy Chataway, Floriana De Angelis, Peter Connick, et al.
Brain : a Journal of Neurology|December 12, 2023
Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndromeHelmut Butzkueven, Anne-Louise Ponsonby, Mark S Stein, et al.
Pageof 3